BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Dear Doctor Letter (Rote-Hand-Brief) on azithromycin: increased recurrence of haematological malignancies and mortality in patients following haematopoietic stem cell transplantation (HSCT) under azithromycin

Active substance: azithromycin

The clinical trial ALLOZITHRO on the prevention of bronchiolitis obliterans syndrome (BOS) in patients after allogeneic haematopoietic stem cell transplantation (HSCT) was discontinued prematurely.

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 948KB, File is accessible

Use of cookies

Cookies help us to provide our services. By using our website you agree that we can use cookies. Read more about our Privacy Policy and visit the following link: Privacy Policy (only in German)

OK